Precision Tumor Medicine and Drug Targets

Author(s): Wei Liu , Xiaoji Wang , Hailiang Zhu* , Yongtao Duan* .

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 17 , 2019

Become EABM
Become Reviewer

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin., 2018, 68(6), 394-424.
[2]
Collins, F.S.; Varmus, H. A new initiative on precision medicine. Eng. J. Med, 2015, 372(9), 793-795.
[3]
Yong-Tao, D.; Chetan, B.S.; Wei, L.; Kunjal, V.S.; Yongfang, Y. New promises to cure cancer and other genetic diseases/disorders: Epi-drugs through epigenetics. Curr. Top. Med. Chem., 2019, 19, 1-23.
[4]
Yongtao, D.; Wei, L.; Liang, T.; Yanna, M.; Chuanjun, S. Targeting tubulin-colchicine site for cancer therapy: Inhibitors, antibody- drug conjugates and degradation agents. Curr. Top. Med. Chem., 2019, 19, 1-16.
[5]
Aronson, S.J.; Rehm, H.L. Building the foundation for genomics in precision medicine. Nature, 2015, 526, 336.
[6]
Deng, X.; Nakamura, Y. Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol. Sci., 2017, 38(1), 15-24.
[7]
Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett., 2017, 387, 61-68.
[8]
Turley, S.J.; Cremasco, V.; Astarita, J.L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol., 2015, 15, 669-682.
[9]
Syn, N.L.; Teng, M.W.L.; Mok, T.S.K.; Soo, R.A. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncol., 2017, 18(12), e731-e41.
[10]
Meeusen, E.; Lim, E.; Mathivanan, S. Secreted tumor antigens-immune biomarkers for diagnosis and therapy. Proteomics, 2017, 17(23-24)1600442


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 17
Year: 2019
Page: [1488 - 1489]
Pages: 2
DOI: 10.2174/156802661917190828111130

Article Metrics

PDF: 17
HTML: 2